###begin article-title 0
Hormone-Sensitive Lipase Serine Phosphorylation and Glycerol Exchange Across Skeletal Muscle in Lean and Obese Subjects
###end article-title 0
###begin p 1
###xml 45 67 45 67 <email xmlns:xlink="http://www.w3.org/1999/xlink">j.jocken@hb.unimaas.nl</email>
Corresponding author: Dr. Johan W.E. Jocken, j.jocken@hb.unimaas.nl
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE</bold>
OBJECTIVE-Increased intramuscular triacylglycerol (IMTG) storage is a characteristic of the obese insulin-resistant state. We aimed to investigate whether a blunted fasting or beta-adrenergically mediated lipolysis contributes to this increased IMTG storage in obesity.
###end p 3
###begin p 4
###xml 0 27 0 27 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS</bold>
###xml 114 115 114 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 116 117 116 117 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 103 106 <span type="species:ncbi:9606">men</span>
RESEARCH DESIGN AND METHODS-Forearm skeletal muscle lipolysis was investigated in 13 lean and 10 obese men using [2H5]glycerol combined with the measurement of arteriovenous differences before and during beta-adrenergic stimulation using the nonselective beta-agonist isoprenaline (ISO). Muscle biopsies were taken from the vastus lateralis muscle before and during ISO to investigate hormone-sensitive lipase (HSL) protein expression and serine phosphorylation.
###end p 4
###begin p 5
###xml 0 7 0 7 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS</bold>
###xml 123 124 123 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 189 190 189 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 237 240 237 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 242 243 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 260 263 260 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 265 266 265 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 320 323 320 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">565</sup>
###xml 325 326 325 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 570 571 570 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 769 772 769 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 842 843 842 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
RESULTS-Baseline total glycerol release across the forearm was significantly blunted in obese compared with lean subjects (P = 0.045). This was accompanied by lower HSL protein expression (P = 0.004), HSL phosphorylation on PKA sites Ser563 (P = 0.041) and Ser659 (P = 0.09), and HSL phosphorylation on the AMPK site Ser565 (P = 0.007), suggesting a blunted skeletal muscle lipolysis in obesity. Total forearm glycerol uptake during baseline did not differ significantly between groups, whereas higher net fatty acid uptake across the forearm was observed in the obese (P = 0.064). ISO induced an increase in total glycerol release from skeletal muscle, which was not significantly different between groups. Interestingly, this was accompanied by an increase in HSL Ser659 phosphorylation in obese subjects during ISO compared with baseline (P = 0.008).
###end p 5
###begin p 6
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS</bold>
CONCLUSIONS-Obesity is accompanied by impaired fasting glycerol release, lower HSL protein expression, and serine phosphorylation. It remains to be determined whether this is a primary factor or an adaptation to the obese insulin-resistant state.
###end p 6
###begin p 7
Published ahead of print at  on 8 April 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 32 36 32 36 <related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" vol="57" page="1784" id="N0x1e2b0d0N0x42ec160" xlink:href="18586910" ext-link-type="pubmed">1784</related-article>
See accompanying commentary, p. 1784.
###end p 9
###begin p 10
###xml 168 169 168 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 318 319 318 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 320 321 320 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 550 551 550 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 786 787 783 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 788 789 785 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 1217 1218 1214 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
The obese insulin-resistant state is characterized by increased triacylglycerol (TAG) storage in adipose and nonadipose tissues (ectopic fat), such as skeletal muscle (1). A strong link between increased intramuscular TAG (IMTG) stores and skeletal muscle insulin resistance has been shown in lean and obese subjects (2,3). Recent studies have, however, indicated that intramuscular accumulation of lipid intermediates rather than TAG per se may be the direct cause of skeletal muscle insulin resistance, through interference with insulin signaling (4). Impaired uptake and a reduced oxidation of fatty acids has been reported in skeletal muscle under postabsorptive conditions, during beta-adrenergic stimulation and moderate-intensity exercise in obese subjects with type 2 diabetes (5-7). Besides impaired fatty acid handling, disturbances in the regulation of skeletal muscle lipolysis may contribute to the increased storage of IMTG and lipid metabolites. So far, little is known on the in vivo regulation of skeletal muscle lipolysis in obesity. Data from our laboratory indicate that the catecholamine-induced increase in interstitial glycerol concentration and local blood flow are blunted in obese subjects (8), a factor that may contribute to an increase in content of muscle TAG and diacylglycerol.
###end p 10
###begin p 11
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 418 421 418 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 426 429 426 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">565</sup>
###xml 434 437 434 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">600</sup>
###xml 442 445 442 445 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 454 457 454 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">660</sup>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 594 597 594 597 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 602 605 602 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 614 617 614 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink">660</sup>
###xml 667 670 667 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 709 711 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 871 874 871 874 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 923 926 923 926 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 1050 1052 1050 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 1182 1185 1182 1185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">565</sup>
###xml 1234 1236 1234 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 1352 1355 1352 1355 <sup xmlns:xlink="http://www.w3.org/1999/xlink">565</sup>
###xml 1481 1484 1481 1484 <sup xmlns:xlink="http://www.w3.org/1999/xlink">565</sup>
###xml 1595 1597 1595 1597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 198 204 <span type="species:ncbi:9606">humans</span>
###xml 1084 1090 <span type="species:ncbi:9913">bovine</span>
###xml 1242 1247 <span type="species:ncbi:9606">human</span>
###xml 1556 1561 <span type="species:ncbi:9606">human</span>
Although the molecular mechanisms that underlie muscle lipolysis are not known in detail, it has been shown that hormone-sensitive lipase (HSL) is expressed in skeletal muscle of rodents (9,10) and humans (11). HSL activity appears to be regulated by site-specific phosphorylation on several serine residues. It has been demonstrated that skeletal muscle HSL can be phosphorylated on at least five serine residues (Ser563, Ser565, Ser600, Ser659, and Ser660) (11-13). Catecholamines increase intracellular cyclic AMP concentration, resulting in the activation of protein kinase A (PKA). HSL Ser563, Ser659, and Ser660 are major PKA phosphorylation sites, although Ser563 may not affect HSL activity directly (14). It is still unclear which of the PKA phosphorylation sites on HSL are important in mediating the effect of catecholamines on in vivo muscle HSL activity. Ser659 appears to be a likely candidate because HSL Ser659 phosphorylation and HSL activity show a similar response to exercise with concomitant increase in circulating epinephrine (13). In vitro studies on purified bovine adipocyte HSL have shown that AMP-activated protein kinase (AMPK) phosphorylates HSL on Ser565, thereby abolishing PKA-induced HSL activation (15). In human skeletal muscle, changes in AMPK activity during exercise were also associated with an increased HSL Ser565 phosphorylation, but this was not accompanied by an increased HSL activity, suggesting that AMPK can phosphorylate HSL on Ser565 but that AMPK is of minor importance as a regulator of HSL activity in human skeletal muscle during exercise (11).
###end p 11
###begin p 12
###xml 337 338 337 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 339 340 339 340 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 780 783 774 777 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 788 791 782 785 <sup xmlns:xlink="http://www.w3.org/1999/xlink">565</sup>
###xml 800 803 794 797 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
So far, limited data are available on the differences in in vivo regulation of skeletal muscle lipolysis between lean and obese subjects. The aim of the present study was to investigate whether in vivo baseline and/or catecholamine-induced lipolysis is impaired in skeletal muscle of obese compared with lean subjects. For this reason, [2H5]glycerol tracer methodology was used to investigate in vivo whole-body and regional forearm skeletal muscle lipolysis in lean and obese subjects after an overnight fast and during beta-adrenergic stimulation, using the nonselective beta-adrenergic agonist isoprenaline (ISO). To obtain more information on the underlying mechanism at the molecular level, we measured skeletal muscle HSL protein expression and serine phosphorylation on Ser563, Ser565, and Ser659.
###end p 12
###begin title 13
RESEARCH DESIGN AND METHODS
###end title 13
###begin p 14
###xml 84 85 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 145 146 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 147 148 143 144 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 385 386 381 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 387 388 383 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 505 512 501 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 714 716 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 24 29 <span type="species:ncbi:9606">women</span>
###xml 38 41 <span type="species:ncbi:9606">man</span>
###xml 312 315 <span type="species:ncbi:9606">men</span>
Three healthy lean (two women and one man; age 20 +/- 1 years; BMI 22.3 +/- 1.1 kg/m2) subjects participated in a pilot experiment during which [2H5]glycerol enrichment was investigated during 6-h infusion to determine the time required to achieve an isotopic steady state. Thirteen lean and 10 obese nonsmoking men participated in the actual muscle lipolysis experiment during which [2H5]glycerol was infused for 3 h. Clinical characteristics of the subjects included in the experiment are summarized in Table 1. Body weight and body density (by hydrostatic weighing), used for calculations of percent body fat, fat mass, and fat-free mass (FFM), were determined after an overnight fast, as previously described (16). All subjects were in good health as assessed by medical history, were free of any medication, and spent </=3 h/week in organized sports activities. The Medical Ethical Committee of Maastricht University approved the study protocol, and all subjects gave their written informed consent before participating in the study.
###end p 14
###begin title 15
Experimental protocol.
###end title 15
###begin p 16
###xml 56 57 56 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 58 59 58 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 278 280 277 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 304 305 303 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 306 307 305 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 333 335 331 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 341 343 339 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 486 487 484 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 488 489 486 487 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
In a pilot study in three subjects, the time course of [2H5]glycerol enrichment was determined to investigate when steady-state concentrations were achieved. Glycerol enrichment was measured in arterialized blood and venous blood draining the forearm during primed (3 mumol . kg-1) constant infusion of [2H5]glycerol (0.20 mumol . kg-1 . min-1) for 6 h. Blood samples were taken simultaneously from the two sites at baseline for background enrichment (t0) and at 10 time points during [2H5]glycerol infusion (t60, t90, t120, t150, t180, t210, t240, t330, t345, and t360).
###end p 16
###begin p 17
###xml 144 146 143 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 170 171 169 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 172 173 171 172 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 199 201 197 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 207 209 205 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 292 294 290 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 304 306 302 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 411 413 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 925 928 923 926 <sc xmlns:xlink="http://www.w3.org/1999/xlink">fbf</sc>
###xml 1507 1508 1499 1500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
During the actual muscle lipolysis experiment, glycerol enrichment and exchange across the forearm were investigated during primed (3 mumol . kg-1) constant infusion of [2H5]glycerol (0.20 mumol . kg-1 . min-1) for 3 h. After a 120-min baseline period, ISO was infused at a rate of 20 ng . kg-1 FFM . min-1 for 60 min. At this infusion rate, plasma ISO concentrations are comparable in lean and obese subjects (17). At the beginning of the experiment, an arterialized blood sample was taken for measurement of background enrichment. Furthermore, arterialized and deep venous blood samples were taken simultaneously at three baseline time points (t90, t105, and t120) and at three time points during the last 30 min of ISO infusion (t150, t165, and t180). In both the pilot and muscle lipolysis experiment, forearm blood flow (FBF) was measured just before blood sampling to calculate substrate fluxes across the forearm (see fbf). Skeletal muscle biopsies were taken from the vastus lateralis muscle under local anesthesia of skin and fascia (Xylocaine; AstraZeneca, Zoetermeer, the Netherlands) immediately before the baseline period (t0) and just before the end of ISO infusion (t180). Muscle biopsies were immediately frozen in liquid nitrogen and stored at -80degreesC until further analysis. During the experiment, heart rate was recorded continuously by means of a three-lead electrocardiogram (ECG). When heart rate increased >30 beats/min or in case of ECG irregularities, ISO infusion was stopped (n = 2, 1 lean/1 obese).
###end p 17
###begin title 18
Clinical methods.
###end title 18
###begin p 19
###xml 192 196 192 196 <sc xmlns:xlink="http://www.w3.org/1999/xlink">a.m.</sc>
###xml 471 473 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 575 576 569 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 577 578 571 572 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
All subjects were asked to refrain from drinking alcohol and to perform no strenuous exercise for a period of 24 h before the experiment. Subjects came to the laboratory by car or bus at 8:00 a.m. after an overnight fast. Before initiating the experiment, a catheter was inserted retrogradely into a superficial dorsal hand vein to obtain arterialized venous blood. The hand was warmed in a hotbox, which was maintained at 60degreesC to achieve adequate arterialization (18). In the same arm, a second catheter was inserted in a forearm antecubital vein for the infusion of [2H5]glycerol tracer and ISO. In the contralateral arm, a third catheter was introduced retrogradely in an antecubital vein of the forearm for sampling of deep venous blood draining forearm skeletal muscle. The subjects rested in a supine position for the entire duration of the study.
###end p 19
###begin title 20
FBF.
###end title 20
###begin p 21
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
FBF was measured by venous occlusion plethysmography (EC5R plethysmograph; Hokanson, Bellevue, WA) using mercury-in-silastic strain gauges applied to the widest part of the forearm (19). During measurement periods, the hand circulation was occluded by rapid inflation of a sphygmomanometer cuff (E20 rapid cuff inflator; Hokanson) placed around the wrist to a pressure of 200 mmHg. In this way, FBF can be assessed without interference of the hand circulation. A second cuff, placed just above the anticubital fossa, was inflated to 45 mmHg (which was lower than the diastolic blood pressure, which was >70 mmHg in all subjects) to achieve venous occlusion and obtain plethysmographic recordings. During venous occlusion, the plethysmographic recordings reflect the rate of arterial inflow, indicating FBF.
###end p 21
###begin title 22
Muscle lysates.
###end title 22
###begin p 23
###xml 280 281 280 281 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 445 446 445 446 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 461 462 461 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 643 644 635 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
Muscle tissue was freeze-dried; dissected free of all visible adipose tissue, connective tissue, and blood under a microscope; and subsequently homogenized (1:80 [wt/vol]) in a buffer containing 50 mmol/l HEPES (pH 7.5), 150 mmol/l NaCl, 20 mmol/l sodium pyrophosphate, 20 mmol/l l-glycerophosphate, 10 mmol/l NaF, 2 mmol/l sodium orthovanadate, 2 mmol/l EDTA, 1% Nonidet P-40, 10% glycerol, 2 mmol/l phenylmethylsulfonyl fluoride, 1 mmol/l MgCl2, 1 mmol/l CaCl2, 10 mug/ml leupeptin, 10 mug/ml aprotinin, and 3 mmol/l benzamidine. Homogenates were rotated end over end for 1 h at 4degreesC and then cleared by centrifugation for 1 h at 17,500g, 4degreesC. Protein content in the supernatant was measured by the bicinchoninic acid protein assay (Pierce, Rockford, IL).
###end p 23
###begin title 24
Western blotting.
###end title 24
###begin p 25
###xml 56 59 56 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 64 67 64 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">565</sup>
###xml 76 79 76 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 403 406 403 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 434 437 434 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">565</sup>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 474 477 474 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 257 263 <span type="species:ncbi:9986">rabbit</span>
###xml 377 382 <span type="species:ncbi:9940">sheep</span>
###xml 408 413 <span type="species:ncbi:9940">sheep</span>
###xml 448 453 <span type="species:ncbi:9940">sheep</span>
###xml 510 521 <span type="species:ncbi:3704">horseradish</span>
###xml 549 555 <span type="species:ncbi:9986">rabbit</span>
###xml 610 615 <span type="species:ncbi:9940">sheep</span>
Expression of HSL protein and phosphorylation of HSL Ser563, Ser565, and Ser659 was detected by Western blotting on the muscle lysates. The lysates were boiled in Laemmli buffer before being subjected to SDS-PAGE and immunoblotting. Primary antibodies were rabbit anti-HSL (donated by Prof. Cecilia Holm [Department of Cell and Molecular Biology, Lund University, Sweden]) and sheep anti-phospho-HSL Ser563, sheep anti-phospho-HSL Ser565 (11), and sheep anti-phospho-HSL Ser659 (13). Secondary antibodies were horseradish peroxidase-conjugated anti-rabbit (catalog no. P0448; DAKO, Glostrup, Denmark) and anti-sheep (catalog no. 81-8620; Zymed, San Francisco, CA). Antigen/antibody complexes were visualized using enhanced chemiluminescence (ECL+; Amersham Biosciences, Buckinghamshire, U.K.) and quantified by a Kodak Image Station E440CF (Kodak, Glostrup, Denmark).
###end p 25
###begin title 26
Analytical methods.
###end title 26
###begin p 27
###xml 224 225 224 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 941 943 935 937 <sub xmlns:xlink="http://www.w3.org/1999/xlink">IR</sub>
###xml 992 994 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
A small portion of blood was used for the measurement of oxygen saturation to ensure adequate arterialization (ABL510; Radiometer, Copenhagen). Blood was collected in tubes containing EDTA and centrifuged for 10 min at 1,000g, 4degreesC. The supernatant (plasma) was used for the enzymatic colorimetric quantification of fatty acids (NEFA C kit; Wako Chemicals, Neuss, Germany), free glycerol (Boehringer, Mannheim, Germany), and TAG (Sigma, St. Louis, MO) on a COBAS FARA centrifugal spectrophotometer (Roche Diagnostica, Basel, Switzerland). Plasma glucose concentration (ABX Diagnostics, Montpellier, France) and lactate (ABX Diagnostics) were measured enzymatically on a COBAS MIRA automated spectrophotometer (Roche Diagnostica). Plasma insulin was measured with a double antibody radioimmunoassay (Linco Research, St. Charles, MO). Insulin sensitivity was assessed by the homeostasis model assessment index for insulin resistance (HOMAIR), calculated from baseline glucose and insulin (20). Hematocrit was measured using a microcapillary system (Hirschmann Laborgerate, Eberstadt, Germany).
###end p 27
###begin title 28
Isotope enrichment.
###end title 28
###begin p 29
###xml 203 204 202 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 933 935 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
To determine isotopic enrichment of glycerol, samples were first derivatized. One milliliter acetone was added to 150 mul plasma, and each tube was vortexed for 2 min and centrifuged for 20 min at 17,500g, 4degreesC. The supernatant was transferred to a clean tube, dried under nitrogen at 37degreesC, and derivatized using 80 mul ethyl acetate (catalog no. 45765; Sigma-Aldrich, Seelze, Germany) and 80 mul heptafluorobutyric acid anhydride (catalog no. 63164; Pierce). The tubes were vortexed for 2 min and incubated for 1 h at 70degreesC. Samples were then rotated end over end for 5 min at 25degreesC and evaporated under nitrogen at room temperature. Seventy microliters ethyl acetate was added before injection into the gas chromatograph-mass spectrometer (MAT 252; Finnigan, Bremen, Germany) for measurement of glycerol enrichment by selectively monitoring the mass-to-charge ratio of molecular ions 253 and 257 for glycerol (21).
###end p 29
###begin title 30
Calculations.
###end title 30
###begin p 31
The exchange of metabolites across the forearm was calculated by multiplying the arteriovenous plasma concentration difference of metabolites by forearm plasma flow. Plasma flow was calculated as FBF x (1 - hematocrit), with hematocrit expressed as a fraction. A positive net exchange indicates net uptake, whereas a negative net exchange indicates net release.
###end p 31
###begin p 32
The expected deep venous glycerol enrichment, in case of no glycerol uptake, was calculated as arterialized enrichment multiplied by arterialized glycerol concentration and subsequently divided by deep venous glycerol concentration.
###end p 32
###begin p 33
###xml 24 25 24 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 25 26 25 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">a</sub>
###xml 146 147 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 188 190 187 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 196 198 195 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
The rate of appearance (Ra) of glycerol was calculated according to the following steady-state equation:  where TTR is tracer-to-tracee ratio and F is the isotope infusion rate (mumol . kg-1 . min-1).
###end p 33
###begin p 34
###xml 139 140 139 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 141 142 141 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 173 174 173 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 175 176 175 176 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 306 308 306 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 321 323 321 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 334 337 334 337 <sub xmlns:xlink="http://www.w3.org/1999/xlink">art</sub>
###xml 447 449 446 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 462 464 461 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
The fractional extraction (fract) of glycerol across the forearm was calculated by dividing the arteriovenous concentration difference of [2H5]glycerol by the arterialized [2H5]glycerol concentration. Total glycerol uptake across the forearm was then calculated as follows:  where the unit is nmol . 100 ml-1 tissue . min-1; [glycerolart] is arterialized glycerol concentration (mumol/l); and FBF is forearm skeletal muscle blood flow (ml . 100 ml-1 tissue . min-1). Forearm total glycerol release was calculated from the formula:  Net glycerol balance (exchange) was calculated as explained above.
###end p 34
###begin title 35
Statistical analysis.
###end title 35
###begin p 36
###xml 98 99 98 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 267 268 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 455 456 453 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Differences within groups (i.e., between baseline and ISO) were tested using the paired Student's t test (two-sided). Comparisons between groups (at baseline and during ISO infusion and changes from baseline to ISO, respectively) were made using Student's two-sample t test (equal variance assumed). Statistical calculations were performed using SPSS for Macintosh (version 11.0; SPSS, Chicago). Data are presented as mean +/- SE if not otherwise stated. P < 0.05 was considered statistically significant.
###end p 36
###begin title 37
RESULTS
###end title 37
###begin title 38
Pilot experiment.
###end title 38
###begin p 39
###xml 3 9 3 9 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 79 80 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 81 82 81 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 285 291 285 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 342 343 342 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 344 345 344 345 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
In Fig. 1, we show that arterialized and deep venous TTR, obtained with a 6-h [2H5]glycerol infusion, reached a steady state after 1 h of infusion. The measured deep venous enrichment was consistently lower than the expected enrichment, implying uptake of glycerol across the forearm (Fig. 1). In the actual muscle lipolysis experiment (3-h [2H5]glycerol infusion), TTR also reached a steady state after 1 h and remained stable during ISO infusion (data not shown). Thus, our data support the use of a relatively short infusion time (>/=1 h) to accurately study glycerol metabolism.
###end p 39
###begin title 40
Circulating metabolites.
###end title 40
###begin p 41
###xml 103 104 103 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 114 121 114 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 211 212 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 222 229 219 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 308 309 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 318 325 315 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 455 456 452 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 466 473 463 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 692 699 685 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
Baseline plasma-arterialized TAG concentration was twice as high for the obese than the lean subjects (P < 0.001; Table 2). beta-Adrenergic stimulation increased plasma-arterialized TAG concentrations in obese (P = 0.047; Table 2) subjects, whereas in lean subjects, TAG concentrations decreased during ISO (P = 0.08; Table 2). Thus, the change in plasma-arterialized TAG concentrations from baseline to ISO was different between lean and obese subjects (P = 0.004; Table 2). Because of an irregular ECG or failure of the cannulation, there are three individuals less in each group in the ISO experiment. Therefore, Delta values for the remaining 10 lean and 7 obese subjects are included in Table 2. Baseline values for this subgroup did not differ from those of the whole group.
###end p 41
###begin p 42
###xml 187 188 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 201 202 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 237 238 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 251 252 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 286 293 283 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 416 417 410 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 437 444 431 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 579 580 570 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 580 581 571 572 <sub xmlns:xlink="http://www.w3.org/1999/xlink">a</sub>
###xml 610 611 601 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 621 628 612 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 683 684 674 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 694 701 685 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 746 747 737 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 747 748 738 739 <sub xmlns:xlink="http://www.w3.org/1999/xlink">a</sub>
###xml 848 849 836 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 849 850 837 838 <sub xmlns:xlink="http://www.w3.org/1999/xlink">a</sub>
###xml 892 893 880 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 903 910 891 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 943 944 931 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 944 945 932 933 <sub xmlns:xlink="http://www.w3.org/1999/xlink">a</sub>
Baseline plasma-arterialized FFA and glycerol concentrations did not differ significantly between lean and obese subjects. beta-Adrenergic stimulation increased FFA and glycerol in lean (P < 0.001 and P = 0.015, respectively) and obese (P = 0.001 and P < 0.001, respectively) subjects (Table 2). Moreover, the beta-adrenergic-mediated increase in arterialized FFA and glycerol was more pronounced in obese subjects (P = 0.037 and 0.008; Table 2), suggesting a higher whole-body lipolytic response in the obese. Likewise, beta-adrenergic stimulation increased whole-body glycerol Ra in lean and obese subjects (P < 0.001; Table 2), and this increase tended to be higher in the obese (P = 0.067; Table 2). Expressed per unit FFM, baseline glycerol Ra was not significantly different between groups. beta-Adrenergic stimulation increased the glycerol Ra per unit FFM in lean and obese subjects (P < 0.001; Table 2), but this increase in glycerol Ra per unit FFM was not significantly different between groups.
###end p 42
###begin p 43
###xml 123 124 123 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 134 141 134 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 333 334 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 344 351 341 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 463 464 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 474 481 471 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
Plasma-arterialized insulin and lactate concentrations were higher in obese than in lean subjects during baseline and ISO (P = 0.002; Table 2), whereas glucose did not differ significantly between lean and obese subjects in both conditions. beta-Adrenergic stimulation increased circulating insulin concentrations in lean and obese (P < 0.001; Table 2). This increase in circulating insulin concentrations was significantly higher in obese than in lean subjects (P < 0.001; Table 2). Circulating glucose and lactate concentrations were unchanged during beta-adrenergic stimulation.
###end p 43
###begin title 44
Regional forearm metabolism.
###end title 44
###begin p 45
###xml 64 65 64 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 74 81 74 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t3">Table 3</xref>
###xml 183 184 180 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Baseline FBF was not different between lean and obese subjects (P = 0.15; Table 3). FBF was significantly elevated during beta-adrenergic stimulation in both lean and obese subjects (P < 0.001), but the increase in FBF during beta-adrenergic stimulation was not significantly different between groups.
###end p 45
###begin p 46
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 28 29 28 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 250 251 246 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 283 284 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 277 284 273 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
Fractional extraction of [2H5]glycerol from the circulation (lean vs. obese, 40.2 +/- 3.4 vs. 40.5 +/- 6.1%) was not significantly different between groups. Significant glycerol uptake across the forearm was observed in both obese and lean subjects (P < 0.001 compared with 0; Fig. 2A). The increase in total glycerol uptake during beta-adrenergic stimulation was not significantly different between groups.
###end p 46
###begin p 47
###xml 112 113 112 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 123 130 123 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t3">Table 3</xref>
###xml 270 271 270 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 287 288 287 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 281 288 281 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 678 679 674 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 689 696 685 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t3">Table 3</xref>
###xml 788 789 781 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 815 816 808 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 809 816 802 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 1016 1017 1006 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1026 1033 1016 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t3">Table 3</xref>
Baseline net glycerol efflux across the forearm was significantly lower in the obese than in the lean subjects (P = 0.025; Table 3). Accordingly, obese subjects showed significantly less total glycerol release across the forearm at baseline compared with lean subjects (P = 0.045; Fig. 2B). These data indicate a blunted glycerol release during baseline in obese subjects. Total glycerol uptake expressed relative to total glycerol release at baseline was not significantly different between lean and obese subjects (lean vs. obese, 92.7 +/- 13.5 vs. 91.7 +/- 23.9% of total release). Furthermore, obese subjects had higher net fatty acid uptake across the forearm at baseline (P = 0.064; Table 3). beta-Adrenergic stimulation increased total glycerol release in lean and obese subjects (P = 0.037 and 0.042; Fig. 2B), but this increase was not significantly different between groups. Finally, the increase in net lactate efflux during beta-adrenergic stimulation tended to be higher in obese than in lean subjects (P = 0.06; Table 3).
###end p 47
###begin title 48
Total HSL protein expression and serine phosphorylation in the vastus lateralis muscle.
###end title 48
###begin p 49
###xml 92 93 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 164 165 161 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 158 165 155 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 203 206 200 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 208 209 205 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 223 226 220 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink">565</sup>
###xml 228 229 225 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 247 250 244 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 252 253 249 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 318 319 315 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 320 321 317 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 312 321 309 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic>&#8211;<italic>D</italic></xref>
###xml 369 372 366 369 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 377 380 374 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink">565</sup>
###xml 389 392 386 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 538 541 532 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 552 555 546 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink">565</sup>
###xml 611 612 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 605 612 599 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 617 618 611 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 663 666 657 660 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 684 685 678 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 701 702 695 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 695 702 689 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>D</italic></xref>
###xml 738 741 732 735 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
Muscle HSL protein expression was significantly lower in obese compared with lean subjects (P = 0.004) and did not change during beta-adrenergic stimulation (Fig. 3A). Baseline HSL phosphorylation on Ser563 (P = 0.041), Ser565 (P = 0.007), and Ser659 (P = 0.09) was reduced in obese compared with lean subjects (Fig. 3B-D). When corrected for total HSL protein, HSL Ser563, Ser565, and Ser659 phosphorylation was comparable between lean and obese subjects (data not shown). No effect of beta-adrenergic stimulation was observed on HSL Ser563 or HSL Ser565 phosphorylation in both lean and obese subjects (Fig. 3B and C). Obese subjects showed an increased HSL Ser659 phosphorylation (P = 0.008; Fig. 3D), whereas in lean subjects, HSL Ser659 phosphorylation was unchanged after ISO infusion.
###end p 49
###begin title 50
DISCUSSION
###end title 50
###begin p 51
###xml 108 109 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 102 109 102 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 244 247 244 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 252 255 252 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">565</sup>
###xml 264 267 264 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 269 275 269 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 506 509 503 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 97 100 <span type="species:ncbi:9606">men</span>
The present study revealed a blunted fasting muscle glycerol release in obese compared with lean men (Fig. 2B). This blunted skeletal muscle glycerol release was accompanied by a lower total HSL protein expression and phosphorylation of HSL Ser563, Ser565, and Ser659 (Fig. 3), suggesting a blunted fasting muscle lipolysis in obesity. The beta-adrenergic-mediated muscle lipolytic response was not significantly different between lean and obese subjects. In contrast to lean subjects, an increased HSL Ser659 phosphorylation was observed in skeletal muscle of obese subjects during beta-adrenergic stimulation compared with baseline.
###end p 51
###begin title 52
Whole-body lipolysis.
###end title 52
###begin p 53
###xml 771 773 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 905 907 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
There seemed to be a directionally opposite effect of beta-adrenergic stimulation on circulating TAG. Circulating TAG concentrations during beta-adrenergic stimulation increased in obese subjects, whereas lean subjects showed slightly decreased circulating TAG concentration during beta-adrenergic stimulation. This could indicate a greater TAG clearance in lean than in obese subjects after beta-adrenergic stimulation. In the present study, skeletal muscle TAG clearance was not significantly different between groups. Adipose tissue lipoprotein lipase (LPL)-mediated TAG hydrolysis might be the cause of an increased net TAG extraction during beta-adrenergic stimulation. An increased rate of action of LPL has been shown during epinephrine infusion in lean subjects (22). Furthermore, it has been shown that obese subjects have a diminished adipose tissue LPL activity during postprandial conditions (23). However, it remains to be elucidated whether an impaired adipose tissue LPL activity during beta-adrenergic stimulation in obese compared with lean subjects can explain the difference in circulating TAG concentration.
###end p 53
###begin title 54
Baseline muscle glycerol uptake.
###end title 54
###begin p 55
###xml 84 85 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 78 85 78 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 817 819 817 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 941 943 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 634 640 <span type="species:ncbi:9606">humans</span>
###xml 719 725 <span type="species:ncbi:9606">humans</span>
###xml 797 802 <span type="species:ncbi:9606">human</span>
###xml 831 837 <span type="species:ncbi:9606">humans</span>
###xml 935 939 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
The present observation of significant uptake of glycerol across the forearm (Fig. 2A) is in agreement with previous reports (24). The first indications for significant metabolism of glycerol in muscle came from Elia et al. (25) showing 50% loss of enriched glycerol across the forearm. More recently, studies confirmed the finding of significant uptake of glycerol by forearm muscle (26) and vastus lateralis muscle (27). The enzymatic machinery for utilization of glycerol seems to be present in skeletal muscle. Glycerol dehydrogenase, the enzyme that could initiate glycerol oxidation by skeletal muscle, has been demonstrated in humans (28), and oxidation of glycerol by skeletal muscle has been shown to occur in humans (28). Furthermore, glycerol kinase expression has been demonstrated in human muscle cells (29). Thus, in humans, glycerol taken up from the circulation might be oxidized or incorporated into IMTG, as shown in rats (30).
###end p 55
###begin title 56
Baseline muscle glycerol release.
###end title 56
###begin p 57
###xml 102 103 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 96 103 96 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 251 252 251 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 245 252 245 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 898 900 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 901 903 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 1203 1205 1203 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 1327 1329 1327 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 1330 1332 1330 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 1420 1423 1420 1423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 1431 1434 1431 1434 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 1467 1470 1467 1470 <sup xmlns:xlink="http://www.w3.org/1999/xlink">565</sup>
###xml 1598 1601 1598 1601 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 1606 1609 1606 1609 <sup xmlns:xlink="http://www.w3.org/1999/xlink">565</sup>
###xml 1618 1621 1618 1621 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 1895 1898 1895 1898 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 2029 2032 2029 2032 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 2040 2043 2040 2043 <sup xmlns:xlink="http://www.w3.org/1999/xlink">565</sup>
###xml 2149 2151 2149 2151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 2152 2154 2152 2154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 2543 2545 2543 2545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 2930 2932 2930 2932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 2126 2131 <span type="species:ncbi:9606">human</span>
###xml 2907 2912 <span type="species:ncbi:9606">human</span>
###xml 3002 3007 <span type="species:ncbi:9606">human</span>
Our data show a blunted baseline total glycerol release per unit muscle mass in obese subjects (Fig. 2B). This blunted baseline total glycerol release was accompanied by a lower total HSL protein expression in skeletal muscle of obese subjects (Fig. 3A), suggesting a blunted baseline muscle lipolysis. However, it can be argued that glycerol tracer release does not only reflect lipolysis. Thus, a blunted glycerol release might reflect an increased intramuscular glycerol use (i.e., oxidation or TAG synthesis). To our knowledge, our data provide the first indication of a reduced muscle HSL protein expression in obese compared with lean subjects. It is well known that expression of HSL is markedly decreased in subcutaneous adipocytes and differentiated adipocytes from obese subjects. This suggests that, at least in adipose tissue, a decreased HSL expression is a primary defect in obesity (31,32). However, we cannot exclude that the blunted muscle lipolysis in obese subjects was a secondary phenomenon caused by a higher degree of hyperinsulinemia. Still, it has been suggested that muscle lipolysis is primarily regulated by substrate supply and to a lesser degree is under hormonal control (33). This seems to be supported by studies showing no apparent suppression of in vivo skeletal muscle lipolysis by insulin (34,35). Furthermore, our data suggest that phosphorylation of HSL on the PKA target sites Ser563 and Ser659, and on the AMPK target site Ser565, was lower in obese than in lean subjects. It should be recognized, however, that when corrected for total HSL protein, HSL Ser563, Ser565, and Ser659 phosphorylation was comparable between lean and obese subjects, suggesting that a similar percentage of HSL molecules was phosphorylated on these three serine sites in lean and obese subjects. Nevertheless, the reduced absolute number of HSL molecules phosphorylated on Ser659 may at least partly explain the blunted baseline glycerol release in obese compared with lean subjects. On the other hand, HSL Ser563 and Ser565 phosphorylation have been suggested not to be major regulators of HSL activity in human skeletal muscle (11,13). Thus, the reduced phosphorylation of HSL on these two sites may not have been important in determining the blunted baseline lipolysis in obese subjects. For practical reasons, the arteriovenous differences were measured across the forearm muscle, and biopsies were taken from the vastus lateralis muscle. Because there may be heterogeneity in lipolysis between different muscle groups (36), the combination of forearm substrate fluxes with lipolytic enzymes in muscle biopsies from the thigh has to be interpreted with caution. Finally, it should be mentioned that other lipases might also contribute to the blunted baseline muscle glycerol release observed in obese subjects. Recently, we identified adipose triglyceride lipase (ATGL) expression in human skeletal muscle (37). More research is needed to elucidate the potential role of ATGL in human skeletal muscle lipolysis.
###end p 57
###begin title 58
Baseline net muscle fatty acid uptake.
###end title 58
###begin p 59
###xml 153 154 153 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
An increased basal net fatty acid uptake was observed across the forearm of obese subjects. An impaired fatty acid uptake and oxidation by both the leg (5) and the arm (21,38) have been observed previously in obese type 2 diabetic subjects compared with healthy individuals. Disturbances in fatty acid handling and an impaired muscle lipolysis may contribute to the increased IMTG storage in obese subjects. However, because this also depends on lipid turnover, both TAG synthesis and breakdown have to be known to draw final conclusions with respect to the mechanisms underlying increased IMTG content in obesity. For practical reasons and because our primary objective was to study glycerol metabolism, in the present study, no carbon-labeled long-chain fatty acid tracer was used to measure fluxes and oxidation rates across the forearm.
###end p 59
###begin title 60
Muscle glycerol release during beta-adrenergic stimulation.
###end title 60
###begin p 61
###xml 393 394 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 864 866 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 1009 1011 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 1175 1177 1166 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 1030 1034 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
The present results showed equal forearm glycerol release during systemic infusion of the nonselective beta-adrenergic agonist ISO in lean and obese subjects, suggesting a comparable lipolytic response. Previously, in situ microdialysis using a beta-2 agonist, salbutamol, showed a blunted lipolysis in the gastrocnemius muscle of obese insulin-resistant subjects compared with lean subjects (8). Differences in systemic versus local infusion of beta-adrenergic agonists might partly explain this discrepancy. Also, in microdialysis studies, interstitial glycerol is used as a measure of lipolysis. As mentioned previously, glycerol is taken up by skeletal muscle, suggesting that interstitial glycerol may not reflect the overall rate of lipolysis but may instead be the net result of TAG and glycerol metabolism in muscle, thus reflecting net glycerol turnover (39). Finally, there may be marked heterogeneity in lipolysis between different muscle groups, possibly correlated to composition of fiber types (36). Accordingly, in rats, it was shown that muscles with a majority of type 1 fibers had greater HSL activity compared with muscles with a majority of type 2 fiber (10). The higher content of type 1 fibers in the gastrocnemius muscle compared with forearm muscle may not only cause a generally higher lipolytic sensitivity to beta-adrenergic stimulation but may also influence the difference in beta-adrenergically stimulated lipolysis between lean and obese subjects.
###end p 61
###begin p 62
###xml 61 63 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 286 289 283 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 523 526 517 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 671 674 665 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 760 762 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 805 807 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 867 870 861 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 1068 1071 1059 1062 <sup xmlns:xlink="http://www.w3.org/1999/xlink">660</sup>
###xml 1145 1147 1136 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 1179 1182 1170 1173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">660</sup>
###xml 1268 1271 1259 1262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 1407 1410 1395 1398 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 1509 1511 1497 1499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 1512 1514 1500 1502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 1530 1533 1518 1521 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 1640 1643 1628 1631 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 1720 1722 1708 1710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 39 45 <span type="species:ncbi:9913">bovine</span>
###xml 468 471 <span type="species:ncbi:9606">men</span>
###xml 476 481 <span type="species:ncbi:9606">women</span>
###xml 737 742 <span type="species:ncbi:9606">human</span>
###xml 1697 1702 <span type="species:ncbi:9606">human</span>
It is known from studies with purified bovine adipocyte HSL (15) and in different cell lines transfected with wild-type and mutant forms of HSL (14) that beta-adrenergic stimulation increases HSL activity through phosphorylation on several serine residues. In the present study, HSL Ser659 phosphorylation significantly increased during beta-adrenergic stimulation in skeletal muscle of obese subjects, whereas no effect was seen in lean subjects. A previous study in men and women during exercise has shown that muscle Ser659 phosphorylation and muscle HSL activity show a very similar pattern with respect to exercise response and dependency on sex, indicating that Ser659 serves an important role in the regulation of HSL activity in human skeletal muscle (13), as has been demonstrated in adipocytes (14). It can be speculated that obese subjects increase HSL Ser659 phosphorylation during beta-adrenergic stimulation to deal with a reduced total HSL protein expression, increasing muscle HSL activity to a level comparable with lean subjects. In addition, HSL Ser660 appears to be a major PKA target site and HSL activity-controlling site (14). In the present study, HSL Ser660 phosphorylation was not measured. Finally, phosphorylation of the PKA target site Ser563 on HSL did not increase significantly during beta-adrenergic stimulation. This is in accordance with previous studies, in which HSL Ser563 phosphorylation was not increased during exercise despite an increase in circulating epinephrine (11,13). Maybe HSL Ser563 is already maximally phosphorylated in the basal, resting state. Moreover, it has been argued that HSL Ser563 may not be an important regulator of HSL activity in human skeletal muscle (11).
###end p 62
###begin title 63
Muscle lactate release during beta-adrenergic stimulation.
###end title 63
###begin p 64
###xml 391 393 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 434 436 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
Net lactate release across the forearm increased during beta-adrenergic stimulation. This increase was higher in obese compared with lean subjects, suggesting that the glycolytic flux was stimulated to a greater extent by ISO in obese than in lean subjects. This seems in line with previous findings showing an increased lactate release during beta-adrenergic stimulation in obese subjects (17) that persisted after weight reduction (40), indicating that this disturbance might be an early factor in the etiology of obesity.
###end p 64
###begin title 65
Limitations of the study.
###end title 65
###begin p 66
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 450 452 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r43">43</xref>
Considering the increased discomfort and risk associated with arterial catheters, we used arterialized hand vein blood as substitute for arterial blood. Arterialized blood has been shown to be an acceptable alternative to arterial sampling (41,42). Arterialization was achieved by heating the hand in a warm air box at 60degreesC for at least 30 min, which has been previously validated as the appropriate procedure for obtaining arterialized blood (43). In the present study, mean oxygen saturation was 94.5% in both lean and obese subjects, indicating comparable and successful arterialization in both groups.
###end p 66
###begin p 67
###xml 242 245 242 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 253 256 253 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 288 291 288 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">565</sup>
In conclusion, the obese insulin-resistant state is characterized by a reduced muscle glycerol release during baseline fasting conditions, which was accompanied by a lower HSL protein expression and phosphorylation on the PKA target sites Ser563 and Ser659 and on the AMPK target site Ser565. This suggests a blunted fasting skeletal muscle lipolysis in obesity, which may be an important factor contributing to the increased lipid storage in skeletal muscle of obese insulin-resistant subjects. Further studies are necessary to address in more detail whether these disturbances are primary factors or adaptation responses to the obese insulin-resistant state.
###end p 67
###begin p 68
C.R. has received support from the Commission of the European Communities (contract no. LSHM-CT-2004-005272 EXGENESIS), the Copenhagen Muscle Research Centre, and the Ministry of Food, Agriculture and Fisheries. B.K. has received support from the Commission of the European Communities (contract no. LSHM-CT-2004-005272 EXGENESIS), the Copenhagen Muscle Research Centre, and the Ministry of Food, Agriculture and Fisheries. E.E.B. has received a grant from the Netherlands Organization for Health Research and Development (NWO/ZonMw contract no. 015.01.095).
###end p 68
###begin p 69
We greatly appreciate the technical support of Jos Stegen and Anneke van Hees and the willingness of the volunteers to participate in this study. We thank Prof. D. Grahame Hardie (Division of Molecular Physiology, School of Life Sciences, University of Dundee, Dundee, Scotland, U.K.) for providing the anti-phospho-HSL Ser antibodies.
###end p 69
###begin title 70
REFERENCES
###end title 70
###begin p 71
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 62 63 62 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 74 75 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 484 485 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Plasma glycerol TTR during 6-h primed constant infusion of [2H5]glycerol (n = 3) in arterialized blood (blacksquare, square, filled), forearm venous blood (*), and expected forearm venous enrichment (o). The expected deep venous glycerol enrichment was calculated as arterialized enrichment multiplied by arterialized glycerol concentration divided by deep venous glycerol concentration. The measured venous enrichment was consistently lower than the expected deep venous enrichment (P < 0.05), implying uptake of glycerol across the forearm. Values are means +/- SE.
###end p 71
###begin p 72
###xml 23 24 23 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 39 40 39 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 142 143 111 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 144 145 113 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 191 192 160 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 217 218 186 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Total glycerol uptake (A) and release (B) across the forearm during baseline (blacksquare, square, filled) and ISO infusion (square) using a [2H5]glycerol tracer in lean and obese subjects. *P < 0.05 obese vs. lean; #P < 0.05 ISO vs. baseline. Values are means +/- SE.
###end p 72
###begin p 73
###xml 24 25 24 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 34 37 34 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">563</sup>
###xml 39 40 39 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 46 49 46 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">565</sup>
###xml 51 52 51 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 62 65 62 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">659</sup>
###xml 67 68 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 231 232 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 262 263 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
HSL protein expression (A) and Ser563 (B), Ser565 (C), and Ser659 (D) phosphorylation during baseline (blacksquare, square, filled) and ISO infusion (square) in lean and obese subjects. Data are expressed as arbitrary units (AU). *P < 0.05 obese vs. lean; daggerP < 0.01 obese vs. lean in change between baseline and ISO. Values are means +/- SE.
###end p 73
###begin p 74
Subject characteristics
###end p 74
###begin p 75
###xml 40 43 <span type="species:ncbi:9606">men</span>
Data are means +/- SD. All subjects are men.
###end p 75
###begin p 76
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.05 obese vs. lean.
###end p 76
###begin p 77
Circulating arterialized metabolite concentrations during baseline and isoprenaline infusion in lean and obese subjects
###end p 77
###begin p 78
Data are means +/- SE.
###end p 78
###begin p 79
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.05 ISO vs. baseline.
###end p 79
###begin p 80
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.05 obese vs. lean.
###end p 80
###begin p 81
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.05 change (Delta) from baseline obese vs. lean.
###end p 81
###begin p 82
Regional forearm blood flow and net metabolite flux during baseline and isoprenaline infusion in lean and obese subjects
###end p 82
###begin p 83
Data are means +/- SE. Positive flux = net uptake; negative flux = net release.
###end p 83
###begin p 84
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.05 ISO vs. baseline.
###end p 84
###begin p 85
Exchange not different from zero.
###end p 85
###begin p 86
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.05 obese vs. lean.
###end p 86

